anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This pilot study evaluated the relationships between appetite and oral function, and between appetite and the subjective symptoms of decreased oral function.
METHODS: Seventy-one adult dental clinic patients (22 males, 66.0 ± 14.0 years) participated in this study. A Council on Nutrition Appetite Questionnaire score of ≤28 indicated anorexia, and the Mini Nutritional Assessment Short-form, body mass index and skeletal muscle mass index were used to define subject characteristics. Seven oral function tests and seven subjective symptoms related to oral function were evaluated. The relationship between subject characteristics, oral function tests, subjective symptoms and anorexia was analysed using the chi-square test and univariate and multivariate logistic regression.
RESULT: There were significant differences between the normal appetite group and the anorexia group for the 10-item Eating Assessment Tool (EAT-10) survey and the question 'Food remains in the oral cavity after eating' (p < .05). Univariate logistic regression found significant differences in the items of masticatory function, the EAT-10 survey and the question 'Food remains in the oral cavity after eating'. Multivariate logistic regression revealed significant differences in masticatory function (AOR 4.35; 95% CI: 1.03-18.35; p = .045) and EAT-10 (AOR 6.27; 95% CI: 1.40-24.02; p = .016).
CONCLUSION: This pilot study investigated the influence of factors related to oral function on appetite. Relationships were found among poor masticatory function, poor swallowing function and anorexia.
Previous research has shown a strong correlation between sepsis and brain structure. However, whether this relationship represents a causality remains elusive. In this study, we employed Mendelian randomization (MR) to probe the associations of genetically predicted sepsis and sepsis-related death with structural changes in specific brain regions. Genome-wide association study (GWAS) data for sepsis phenotypes (sepsis and sepsis-related death) were obtained from the IEU OpenGWAS. Correspondingly, GWAS data for brain structural traits (volume of the subcortical structure, cortical thickness, and surface area) were derived from the ENIGMA consortium. Inverse variance weighted was mainly utilized to assess the causal effects, while weighted median and MR-Egger regression served as complementary methods. Sensitivity analyses were implemented with Cochran Q test, MR-Egger regression, and MR-PRESSO. In addition, a reverse MR analysis was carried out to assess the possibility of reverse causation. We identified that genetic liability to sepsis was normally significantly associated with a reduced surface area of the postcentral gyrus (β = -35.5280, SE = 13.7465, P = .0096). The genetic liability to sepsis-related death showed a suggestive positive correlation with the surface area of fusiform gyrus (β = 11.0920, SE = 3.6412, P = .0023) and posterior cingulate gyrus (β = 3.6530, SE = 1.6684, P = .0286), While it presented a suggestive negative correlation with surface area of the caudal middle frontal gyrus (β = -11.4586, SE = 5.1501, P = .0261) and frontal pole (β = -1.0024, SE = 0.4329, P = .0206). We also indicated a possible bidirectional causal association between genetic liability to sepsis-related death and the thickness of the transverse temporal gyrus. Sensitivity analyses verified the robustness of the above associations. These findings suggested that genetically determined liability to sepsis might influence the specific brain structure in a causal way, offering new perspectives to investigate the mechanism of sepsis-related neuropsychiatric disorders.
A polypeptide comprises the sequence of SEQ ID NO:2 or a polypeptide with at least 70% amino acid identity over 30 amino acids which has mpa activity. A polynucleotide of SEQ ID NO:1 encoding the polypeptide and an antibody specific to the polypeptide are described. Also described are pharmaceutical compositions and vaccines comprising the polypeptides, polynucleotides or antibodies. The presence of a Mycobacterium avium subspecies paratuberculosis (MAP) infection in a biological sample can be detected by providing a nucleic acid probe comprising a polynucleotide of SEQ ID No:1 or an antibody which is bought into contact with the sample and hybridization is allowed to occur. The formation of any nucleic acid duplex or antibody-antigen complex in the sample is detected. The method can be used to detect inflammatory diseases including CrohnÆs disease, JohneÆs disease and sarcoidosis.
Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
Participants will be instructed to consume a bottle of placebo supplement 15-min prior to each meal (3x/day) for 14 days. Oral placebo will be provided in opaque bottles labelled A or B to maintain condition blinding. Each bottle will contain a 50mL taste-match inert calorie-free placebo.
This project will evaluate the main and interaction effects of four evidence-based smoking cessation components integrated within HIV care in South Africa: (1) intensive behavioural counselling, (2) peer support, (3) combination nicotine replacement therapy (c-NRT), and (4) varenicline. The investigators will also evaluate the implementation and cost-effectiveness of these interventions. This study is a balanced full factorial randomised trial of 660 adults with HIV and will be implemented in two diverse sites in Gauteng, South Africa representing both peri-urban and urban settings.

Participants will be recruited via health care worker-referral or self-referral. Interested patients will be further screened for eligibility. Eligible participants will be administered written informed consent (see "Informed Consent and Assent" section below), and participants will be randomized into one of 16 study conditions for a 12-week intervention period. This will be an open-label trial; neither the participants nor study personnel will be blinded to treatment assignment post randomization, but randomization block assignment will be concealed from the study personnel who will be enrolling participants.
Several recent advances provide multiple health benefits to individuals with type 2 diabetes mellitus (T2DM). Pharmacological therapy is governed by person-centered factors, including comorbidities and treatment goals. Adults with T2DM who have an established/high risk of atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, require a treatment regimen that includes agents that are proven to reduce cardiorenal risk. Weight management plays a key role in reducing glucose for patients with T2DM. A glucose-reduction treatment regimen must consider weight management. Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure, cardiovascular and renal events. Glucagon-like peptide-1 (GLP-1) receptor agonists allow better control of glycemia, promote weight loss and reduce the risk of cardiovascular events. Newer Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 dual agonist, which activate GIP and GLP-1 receptors improve glycemic control and promote greater weight loss than GLP-1 receptor agonists. Several novel drugs are in the clinical development phase. This review pertains to recent advances in pharmacological management of type 2 diabetes.
A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11. Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.
Background: The triglyceride-glucose (TyG) index is a marker of insulin resistance and is associated with cardiovascular mortality and morbidity. Left ventricular remodeling (LVR) after myocardial infarction (STEMI) is associated with poor prognosis. Methods: This retrospective study included 293 STEMI patients. Echocardiography was performed before discharge and 3 months after MI. Results: Compared with the non-LVR group, TyG index value was found to be higher in the LVR group (p < 0.001). Logistic regression analysis showed that higher maximal troponin I value, higher calculated TyG index value, higher N-terminal prohormone of brain natriuretic peptide level and the presence of anterior MI were independently associated with the development of LVR. Conclusion: A high TyG index level may contribute to the prediction of LVR in nondiabetic STEMI patients undergoing successful primary percutaneous coronary intervention.
The process comprises reaction of cpd. of formula (II) where X and Y are two identical or different halogen atoms, with alcohol of formula (III). The resulting intermediate cpds. are treated with 4-aroyl piperazine in an aromatic nucleophilic substitution reaction to give cpds. which are ultimately treated with dilute acid at 20-110 deg.C for 10 minutes to 10 hrs. The prods., of formula (I) where R1 is hydrogen, alkyl, aryl, aralkyl or heteroalkyl, R2 is aryl or heteroaryl and R3 is alkoxyl, are purified by chromatography.
Randomized controlled trials have shown that modest lifestyle changes can prevent or delay the onset of diabetes in adults with pre-diabetes. Unfortunately, despite the increasing prevalence of pre-diabetes and diabetes in all facets of the population, intervention programs needed to achieve these goals are costly and remain unavailable in most clinical settings. Over the past 3 years, we have demonstrated the feasibility of training community instructors to deliver a group-based adaptation of the Diabetes Prevention Program (DPP) lifestyle intervention. In this pilot research, this new delivery model achieves a level of weight reduction that was associated with diabetes prevention and improved cardiometabolic risk factor control in the DPP. This new, large-scale randomized effectiveness trial is designed to evaluate the costs and effectiveness of a partnered approach to identify adults with pre-diabetes in primary care settings, deliver brief advice for diabetes prevention, and provide access to a group-based adaptation of the DPP lifestyle intervention offered by the community. This study will compare costs and outcomes to a standard care, brief clinical counseling approach delivered by Registered Dietitians.
The invention belongs to the technical field of molecular virology and immunology, and provides an alpaca source nano antibody which is screened by using phage display technology and combined with HPV16-L1 protein and an application thereof, wherein the nano antibody comprises a heavy chain variable region VHH which comprises the following CDRs and FRs: CDR1 as shown in SEQ ID NO. 1; CDR2 as shown in SEQ ID NO. 2; CDR3 as shown in SEQ ID NO. 3; FR1 as shown in SEQ ID NO. 4; FR2 as shown in SEQ ID NO. 5; FR3 as shown in SEQ ID NO 6; FR4 as shown in SEQ ID NO. 7. Provides a potential new nano-antibody medicament for the clinical prevention, treatment and detection of the human papilloma virus HPV 16. The molecular weight is small, the immunogenicity is small, the solubility is high, the stability is strong, the medicine can directly reach the infected part, the effect is quick, and a potential treatment strategy is provided for the virus infection.
Patients randomized to the control group will receive the current standard of care (24-hour continuous nutrition). All patients will receive 100% of their daily nutrition.
BACKGROUND: Urinary incontinence is highly prevalent in women while pelvic floor muscle training is recommended as the first-line therapy. However, the exact treatment regimen is poorly understood. Also, patients with pelvic floor muscle damage may have decreased muscle proprioception and cannot contract their muscles properly. Other conservative treatments including electromagnetic stimulation are suggested by several guidelines. Thus, the present study aims to compare the effectiveness of electromagnetic stimulation combined with pelvic floor muscle training as a conjunct treatment for urinary incontinence and different treatment frequencies will be investigated.
METHODS/DESIGN: This is a randomized, controlled clinical trial. We will include 165 patients with urinary incontinence from the outpatient center. Participants who meet the inclusion criteria will be randomly allocated to three groups: the pelvic floor muscle training group (active control group), the low-frequency electromagnetic stimulation group (group 1), and the high-frequency electromagnetic stimulation group (group 2). Both group 1 and group 2 will receive ten sessions of electromagnetic stimulation. Group 1 will be treated twice per week for 5 weeks while group 2 will receive 10 days of continuous treatment. The primary outcome is the change in International Consultation on Incontinence Questionnaire-Short Form cores after the ten sessions of the treatment, while the secondary outcomes include a 3-day bladder diary, pelvic floor muscle function, pelvic organ prolapse quantification, and quality of life assessed by SF-12. All the measurements will be assessed at baseline, after the intervention, and after 3 months of follow-up.
DISCUSSION: The present trial is designed to investigate the effects of a conjunct physiotherapy program for urinary incontinence in women. We hypothesize that this strategy is more effective than pelvic floor muscle training alone, and high-frequency electromagnetic stimulation will be superior to the low-frequency magnetic stimulation group.
PRIMARY OBJECTIVES: I. To assess patients with regards to changes in 25(OH)-D3 changes after supplementation. II. To develop a pharmacokinetic model to describe the time course of the relationship of vitamin D3 (cholecalciferol) supplementation that drives the levels of 25(OH)-D3 during the intensive induction chemotherapy. III. To determine the safety and toxicity of vitamin D3 supplementation in AML patients undergoing intensive induction chemotherapy. SECONDARY OBJECTIVES: I. To explore whether rapid (loading dose of vitamin D3) normalization of 25(OH)-D3 levels will have an effect on the progression free and overall survival. II. To explore whether a relationship exists between the pharmacokinetics of the 25-hydroxy-vitamin D3 and white blood cell count. OUTLINE: Patients with pretreatment 25(OH)-D3 levels 20-31.9 ng/mL (insufficient levels) are randomized to 1 of 2 treatment arms. ARM I: Patients receive a loading dose of cholecalciferol orally (PO) on day 1. Patients then receive lower-dose cholecalciferol PO beginning on day 8. ARM II: Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive higher-dose cholecalciferol PO beginning on day 8. Patients with pretreatment 25(OH)-D3 levels \< 20 ng/mL (deficient levels) receive a loading dose of cholecalciferol PO on days 1 and 8. Patients then receive lower-dose cholecalciferol PO beginning on day 15. For all patients, treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days.
Participating schools will be randomly assigned to one of the 4 study arms. Only the parents from the mSELY-P-alone schools will receive the mSELY-P intervention. Families from these mSELY-P-alone schools will be given the option to use any other version of Toolkit after completion of the Time 2 post-intervention data collection.
The present invention relates to a sugarless infantile common cold granule for curing infantile common cold and influenza and a preparation method thereof. The sugarless infantile common cold granule is a pure Chinese medicinal preparation prepared from the medicines of cablin patchouli herb, forsythia fruit, isatis root, blackened swallowwort root, etc. The sugarless infantile common cold granule is mainly used for treating infantile common cold, influenza and concomitant symptoms of fever, cough, headache, nasal obstruction, rhinorrhea, sneeze, swelling and pain in a throat, etc. The production method comprises the steps that the Chinese herbal medicines are proportioned according to the prescription, and the granule is obtained by refining in an advanced medical preparation technology. As indicated by clinical verification through a clinical pharmacology base station of the ministry of health, namely Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, and children's hospitals of Chengdu city, the total effectual rate of the infantile common cold granule for curing infantile common cold is 79.6%, and the total effective rate is 98.1%. The infantile common cold granule does not have obvious side effect, and is an effective Chinese medicinal preparation for curing infantile common cold (upper respiratory tract infection) currently.
1. A method for the obtaining of therapeutically acceptable beclomethasone dipropionate comprising gamma irradiation at 2 to 9 Kgy of micronized beclomethasone dipropionate. 2. The therapeutically acceptable micronized beclomethasone dipropionate, obtained by method according to claim 1. 3. Method of preparation of suspension of active ingredient described in claim 2, for an aerosol inhalation: a) preparing a suspension of said ingredient, in a turbo-emulsifier provided with a turbine adapted for homogenizing the suspension; b) subjecting the resulting suspension to a further treatment in a high-pressure homogenizer, thereby forming said aerosol inhalable suspension. 4. A process according to claim 3, wherein: a) said ingredient is dispersed, with the aid of said turbo-emulsifier, in an aqueous solution comprising a carrier, optionally sterilized by heating or filtration and optionally containing wetting agents, viscosity-increasing agents, preservatives, stabilizing agents, isotonicity agents and/or buffers; b) resulting suspension is further subjected to homogenizing and micronizing in said high-pressure homogenizer; c) suspension is partitioned in containers. 5. A process according to claims 3-4, in which the volume diameter of at least 90% of the particles is lower than or equal to 5 [mu]m. 6. A process according to claims 3-4, where the high-pressure homogenization treatment occurs at pressures from 500 to 1000 bars. 7. A process according to claims 3-4, wherein said high-pressure homogenization treatment occurs at pressures from 600 to 800 bars. 8. The process according to claims 3-4 wherein the turbo-emulsifier operates at 2000-3000 r. p. m. and for 15-20 minutes. 9. The process according to claims 3-4 wherein homogenization treatment is effected in one cycle of treatment. 10. The process according to claims 6-7 wherein homogenization treatment is effected in one cycle of treatment. 11. The use of product by claim 2 for preparation of pharmaceutical drugs for treatment of an allergic condition and/or inflammatory condition of the nose or lungs. 12. The use by claim 11 wherein said condition is bronchopulmonary dysplasia.
The invention discloses a silver-loaded meso-porous silicon-containing rinse-free antibacterial hand sanitizer and its preparation method. the preparation method comprises the following steps: adding a skin-protecting agent into an alcohol substance, heating, stirring and dissolving to form an alcoholic solution; immersing meso-porous silicon into an aqueous solution of silver nitrate, oscillating by a shaking table, taking out meso-porous silicon, and freeze-drying to obtain silver-loaded meso-porous silicon; adding a thickening agent, a surfactant and silver-loaded meso-porous silicon into deionized water so as to form an aqueous solution; and adding the aqueous solution into the alcoholic solution, adding a pH conditioning agent so as to prepare the meso-porous silicon-containing rinse-free antibacterial hand sanitizer. The preparation technology is simple, and cost is low. In addition, by utilizing structural features of meso-porous silicon to load silver, stability and slow-release effect of silver can be enhanced. The hand sanitizer has functions of broad-spectrum bacteriostasis and sterilization, has effects on various bacteria and fungi, and has long-acting antibacterial action. The hand sanitizer becomes a promising novel carrier material in the cosmetics industry.
Muscle disuse induces a decline in muscle strength that exceeds the rate and magnitude of muscle atrophy, suggesting that factors beyond the muscle contribute to strength loss. The purpose of this study was to characterize changes in the brain and neuromuscular system in addition to muscle size following upper limb immobilization in young females. Using a within-participant, unilateral design, 12 females (age: 20.6 ± 2.1 years) underwent 14 days of upper arm immobilization using an elbow brace and sling. Bilateral measures of muscle strength (isometric and isokinetic dynamometry), muscle size (magnetic resonance imaging), voluntary muscle activation capacity, corticospinal excitability, cortical thickness and resting-state functional connectivity were collected before and after immobilization. Immobilization induced a significant decline in isometric elbow flexion (-21.3 ± 19.2%, interaction: P = 0.0440) and extension (-19.9 ± 15.7%, interaction: P = 0.0317) strength in the immobilized arm only. There was no significant effect of immobilization on elbow flexor cross-sectional area (CSA) (-1.2 ± 2.4%, interaction: P = 0.466), whereas elbow extensor CSA decreased (-2.9 ± 2.9%, interaction: P = 0.0177) in the immobilized arm. Immobilization did not differentially alter voluntary activation capacity, corticospinal excitability, or cortical thickness (P > 0.05); however, there were significant changes in the functional connectivity of brain regions related to movement planning and error detection (P < 0.05). This study reveals that elbow flexor strength loss can occur in the absence of significant elbow flexor muscle atrophy, and that the brain represents a site of functional adaptation in response to upper limb immobilization in young females.
The study intends to enroll 100 patients \[ASA 1\] with bilateral symmetrical impacted mandibular third molars requiring surgical removal under local anesthesia. 2% Lidocaine hydrochloride with epinephrine bitartrate 1: 80000 in 3ml quantity will be utilized to achieve local anesthesia at the surgical site on both quadrants. Additional supplementation postoperative at the surgical site will be provided with either 1.5 ml of 0.5% bupivacaine with 1:80000 epinephrine solution or saline based on a split mouth randomized study design using a color and number coded envelop. All procedures will be performed by a single surgeon using a similar technique, under identical conditions at one month apart intervals. Pain scores will be assessed by the patient based on a 10cm Visual Analog Scale at intervals of 2, 4, 6, 12, 24, 36, 48, 72, 96 and 120 hours. The duration of soft tissue anesthesia postoperatively will be recorded by the patient. The number of analgesics ingested over 120 hours will be recorded by the patient. Results will be evaluated statistically by the Wilcoxon test and two tailed test to determine the ratio. Statistical significance will be considered at p \< 0.05.